The peripheral CD138+ population but not the CD138− population contains myeloma clonogenic cells in plasma cell leukaemia patients.
D Chiron, S Surget, S Maïga… - British journal of …, 2012 - search.ebscohost.com
British journal of haematology, 2012•search.ebscohost.com
The article reports that stem cell CD 138< sup>+ molecule is better for targeted therapies in
multiple myeloma (MM) as compared with CD 138< sup>-. It further presents several
characteristics of the nature of B-cells present in these stem cells including these molecules
including B-cells are biased towards plasma cells, it exist in patients with multiple myeloma
(MM), and in cell cycles. It also presents a study which determines that CD 138 are good for
MM patients.
multiple myeloma (MM) as compared with CD 138< sup>-. It further presents several
characteristics of the nature of B-cells present in these stem cells including these molecules
including B-cells are biased towards plasma cells, it exist in patients with multiple myeloma
(MM), and in cell cycles. It also presents a study which determines that CD 138 are good for
MM patients.
Abstract
The article reports that stem cell CD 138+ molecule is better for targeted therapies in multiple myeloma (MM) as compared with CD 138-. It further presents several characteristics of the nature of B-cells present in these stem cells including these molecules including B-cells are biased towards plasma cells, it exist in patients with multiple myeloma (MM), and in cell cycles. It also presents a study which determines that CD 138 are good for MM patients.
search.ebscohost.com